MARKETRESEARCH
Uploaded on Apr 4, 2024
Category
Health & Medicine
According to the latest research report by IMARC Group, The global dry eye syndrome market size reached US$ 4.8 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 7.5 Billion by 2032, exhibiting a growth rate (CAGR) of 5% during 2024-2032. More Info:- https://www.imarcgroup.com/dry-eye-syndrome-market
Category
Health & Medicine
Dry Eye Syndrome Market Growth, Demand and Challenges of the Key Industry Players 2024-2032
Global Dry Eye Syndrome
Market Research and
Forecast Report 2024-
2032
Format: PDF+EXCEL
© 2023 IMARC All Rights Reserved
About IMARC Group
In ternat ional Market Analys is Research and Consul t ing Group is a leading adv iser on management
s t rategy and market research wor ldwide. We par tner wi th c l ients in a l l regions and indust ry
vert ica ls to ident i fy thei r h ighest -value oppor tuni t ies, address thei r most cr i t ica l chal lenges, and
t ransform thei r bus inesses.
IMARC’s in format ion products inc lude major market , sc ient i f ic , economic and technological
developments for bus iness leaders in pharmaceut ica l , indust r ia l , and h igh technology
organizat ions. Market forecasts and indust ry analys is for b iotechnology, advanced mater ia ls ,
chemicals , food and beverage, t ravel and tour ism, nanotechnology and novel process ing methods
are at the top of the company’s exper t ise.
IMARC’s ta i lored approach combines unfathomable ins ight in to the dynamics o f companies and
markets wi th c lose cooperat ion at a l l levels of the c l ient organizat ion. This ensures that our c l ients
achieve unmatchable compet i t ive advantage, bui ld more pro f ic ient organizat ions, and secure
las t ing resul ts .
Acco r d ing t o t he l a t e s t r epo r t by I M ARC G r oup , t i t l ed " Dr y E ye Synd rom e M arke t :
G l o ba l I ndu st ry T re nds , Sh are , S i ze , G row t h , O pp or t u n i t y an d Fo recas t 20 24 -
2032 , " t he g loba l d r y eye synd r om e m a r ke t s i ze r eac hed U S$ 4 . 8 B i l l i on i n 2023 .
Dr y Eye Synd r om e i s a com m on eye co nd i t i on cha r ac t e r i zed by i n ad equ a t e
l ub r i c a t i on and m o is t u r e on t he su r f ace o f t h e ey e . I t oc cu r s when t he t ea r g lan ds
Report f a i l t o p r odu ce en ough t e a r s o r whe n t he t ea r s ev apo r a t e t oo qu i ck l y , r esu l t i ng i n
d r yn ess , i r r i t a t i o n , and d i s com f o r t . I t i n c lude s s ym p t om s su ch as a g r i t t y o r san dy
Highlight and sen sa t i on i n t h e eye s , r edn ess , s t i ng in g o r bu r n ing sen sa t i on s , exc ess i ve t ea r i ng , b lu r r ed v is i on , and s ens i t i v i t y t o l i g h t .
The r e a r e se ve r a l un de r l y i ng cau ses o f d r y eye sy nd r om e , i nc lu d ing ag in g , ho r m ona l
Description cha ng es , c e r t a in m ed ica t i o ns , m ed ica l cond i t i ons su ch as au t o im m une d i s o r de r s ,
env i r onm e n t a l f ac t o r s , and l i f e s t y le cho i c es . S om e c om m on l y used t r ea t m en t s
i nc lud e t he use o f a r t i f i c i a l t e a r s o r l u b r i ca t i ng eye d r ops t o p r ov ide t em por a r y
r e l i e f .
Reque st f o r a P DF s ampl e o f t h i s repor t :
h t t p s : / / www. im ar c g r ou p . com / d r y - eye - synd r om e - m ar ke t / r equ es t s am p le
Report Description
G lo b a l D r y E y e S y n d r o m e M a r k e t T r e n d s :
L i f e s t y l e c h a n g e s a n d i n c r e a s e d s c r e e n t i m e i s d r i v i n g t h e g l o b a l m a r k e t . M o r e o v e r , w i t h t h e w i d e s p r e a d u s e o f d i g i t a l d e v i c e s
s u c h a s s m a r t p h o n e s , t a b l e t s , a n d c o m p u t e r s , i n d i v i d u a l s a r e e x p o s e d t o p r o l o n g e d p e r i o d s o f s c r e e n v i e w i n g , l e a d i n g t o
d e c r e a s e d b l i n k r a te s a n d i n c r e a s e d e v a p o r a t i o n o f t e a r s . T h i s p r o l o n g e d v i s u a l t a s k i n g a n d r e d u c e d b l i n k i n g c o n t r i b u te t o t h e
d e v e l o p m e n t o f d r y e y e s y m p t o m s , t h e r e b y f u e l i n g t h e d e m a n d f o r D E S t r e a tm e n ts . B e s i d e s , w i t h t h e g l o b a l p o p u l a t i o n a g i n g , t h e
p r e v a l e n c e o f D E S i s e x p e c t e d t o i n c r e a s e , l e a d i n g t o a g r e a t e r d e m a n d f o r e f f e c t i v e t r e a t me n t s a n d m a n a g e m e n t o p t i o n s .
F u r t h e r m o r e , v a r i o u s e n v i r o n m e n t a l f a c to r s , s u c h a s p o l l u t i o n a n d d r y c l i m a t e s , a r e a u g m e n t i n g t h e D E S m a r k e t a s e x p o s u r e t o
e n v i r o n m e n t a l p o l l u t a n t s , a l l e r g e n s , a n d i r r i t a n t s c a n t r i g g e r o r e x a c e r b a t e d r y e y e s y m p to m s , t h u s c a t a l y z i n g t h e m a r k e t .
A d d i t i o n a l l y , l i v i n g i n r e g i o n s w i t h d r y c l i m a te s o r s p e n d i n g t i m e i n a i r - c o n d i t i o n e d o r h e a te d e n v i r o n m e n ts c a n l e a d t o i n c r e a s e d
e v a p o r a t i o n o f t e a r s a n d w o r s e n e d D E S s y m p t o m s . A l o n g w i t h t h i s , c o n t i n u a l a d v a n c e m e n ts i n d i a g n o s t i c t e c h n o l o g i e s a n d
t e c h n i q u e s h a v e i m p r o v e d t h e a c c u r a c y a n d e f f i c i e n c y o f D E S d i a g n o s i s , a l l o w i n g f o r e a r l i e r d e t e c t i o n a n d i n t e r v e n t i o n . T h i s i s
c r e a t i n g a p o s i t i v e ma r k e t o u t l o o k .
L o o k in g f o r w a r d , t h e m a r k e t v a l u e i s p r o j e c t e d t o r e a c h U S $ 7 . 5 B i l l i o n b y 2 0 3 2 , e x p a n d i n g a t a C A G R o f 5 % d u r i n g 2 0 2 4 -
2 0 3 2 .
V ie w R e p o r t T O C , F i g u r e s a n d T a b l e s : h t t p s : / / w w w . i m a r c g r o u p . c o m / d r y - e y e - s y n d r o m e - m a r k e t
Breakup by Disease Type:
• Evaporat ive Dry Eye Syndrome
• Aqueous Dry Eye Syndrome
Breakup by Drug Type:
• Anti- infl ammatory Drugs
Report • Lubr icant Eye Drops
• Autologous Serum Eye Drops
Segmentation
Breakup by Product:
• Liquid Drops
• Gel
• Liquid Wipes
• Eye Ointment
• Others
Breakup by Distribution Channel:
• Hospital Pharmacies
• Retai l Pharmacies
• Online Pharmacies
Breakup by Region:
Report
• North America
Segmentation • Europe
• Asia Pacifi c
• Middle East and Afr ica
• Latin America
• Akorn Operating Company LLC
• Alimera Science
• Allergan plc.
• Auven Therapeutics
Competitive
• Bausch + Lomb Incorporated
Landscape • GlaxoSmithKl ine plc
with Key • Nicox S.A.
• Novart is AG
Players
• Otsuka Holdings Co., Ltd.
• Santen Pharmaceutical Co., Ltd.
What was the size of the global dry eye syndrome
market in 2023?
What is the expected growth rate of the global dry
eye syndrome market during 2024-2032?
Key What are the key factors driving the global dry eye
syndrome market?
Questions
What has been the impact of COVID-19 on the
Answered in global dry eye syndrome market?
the Report What is the breakup of the global dry eye syndrome
market based on the disease type?
What is the breakup of the global dry eye syndrome
market based on the drug type?
What is the breakup of the global dry eye syndrome
market based on the product?
What is the breakup of the global dry eye syndrome
market based on the distribution channel?
Key What are the key regions in the global dry eye
syndrome market?
Questions
Answered in Who are the key companies/players in the global dry eye syndrome market?
the Report
1 P r e f a c e
2 S c o p e a n d M e t h o d o l o g y
2 . 1 O b j e c t i v e s o f t h e S t u d y
2 . 2 S t a k e h o l d e r s
2 . 3 D a t a S o u r c e s
2 . 3 . 1 P r i m a r y S o u r c e s
2 . 3 . 2 S e c o n d a r y S o u r c e s
2 . 4 M a r k e t E s t i m a t i o n
Table of 2 . 4 . 1 B o t t o m - U p A p p r o a c h 2 . 4 . 2 T o p - D o w n A p p r o a c h 2 . 5 F o r e c a s t i n g M e t h o d o l o g y
3 E x e c u t i v e S u m m a r y
4 I n t r o d u c t i o n
4 . 1 O v e r v i e w
Contents 4 . 2 K e y I n d u s t r y T r e n d s5 G l o b a l D r y E y e S y n d r o m e M a r k e t
5 . 1 M a r k e t O v e r v i e w
5 . 2 M a r k e t P e r f o r m a n c e
5 . 3 I m p a c t o f C O V I D - 1 9
5 . 4 M a r k e t B r e a k u p b y D i s e a s e T y p e
5 . 5 M a r k e t B r e a k u p b y D r u g T y p e
5 . 6 M a r k e t B r e a k u p b y P r o d u c t
5 . 7 M a r k e t B r e a k u p b y D i s t r i b u t i o n C h a n n e l s
5 . 8 M a r k e t B r e a k u p b y R e g i o n
5 . 9 M a r k e t F o r e c a s t
6 M a r k e t B r e a k u p b y D i s e a s e T y p e
6 . 1 E v a p o r a t i v e D r y E y e S y n d r o m e
6 . 1 . 1 M a r k e t T r e n d s
6 . 1 . 2 M a r k e t F o r e c a s t
6 . 2 A q u e o u s D r y E y e S y n d r o m e
6 . 2 . 1 M a r k e t T r e n d s
6 . 2 . 2 M a r k e t F o r e c a s t
7 M a r k e t B r e a k u p b y D r u g T y p e
7 . 1 A n t i - i n f l a m m a t o r y D r u g s
7 . 1 . 1 M a r k e t T r e n d s
7 . 1 . 2 M a r k e t F o r e c a s t
7 . 2 L u b r i c a n t E y e D r o p s
7 . 2 . 1 M a r k e t T r e n d s
7 . 2 . 2 M a r k e t F o r e c a s t
7 . 3 A u t o l o g o u s S e r u m E y e D r o p s
7 . 3 . 1 M a r k e t T r e n d s
7 . 3 . 2 M a r k e t F o r e c a s t
Table of 8 M a r k e t B r e a k u p b y P r o d u c t 8 . 1 L i q u i d D r o p s
8 . 1 . 1 M a r k e t T r e n d s
8 . 1 . 2 M a r k e t F o r e c a s t
Contents 8 . 2 G e l 8 . 2 . 1 M a r k e t T r e n d s
8 . 2 . 2 M a r k e t F o r e c a s t
8 . 3 L i q u i d W i p e s
8 . 3 . 1 M a r k e t T r e n d s
8 . 3 . 2 M a r k e t F o r e c a s t
8 . 4 E y e O i n t m e n t
8 . 4 . 1 M a r k e t T r e n d s
8 . 4 . 2 M a r k e t F o r e c a s t
8 . 5 O t h e r s
8 . 5 . 1 M a r k e t T r e n d s
8 . 5 . 2 M a r k e t F o r e c a s t
9 M a r k e t B r e a k u p b y D i s t r i b u t i o n C h a n n e l
9 . 1 H o s p i t a l P h a r m a c i e s
9 . 1 . 1 M a r k e t T r e n d s
9 . 1 . 2 M a r k e t F o r e c a s t
F o r m o r e i n f o r m a t i o n , v i s i t :
h t t p s : / / w w w. i m a rc g ro u p . c o m / d r y - e ye - s y n d ro m e - m a r ke t / t o c
Disclaimer
© 2023 IMARC Al l R ights Reserved
Th is Pub l i ca t ion and a l l i t ’ s con ten ts un less o therw ise men t i oned a re copy r i gh ted in the name o f
I n t e rna t i ona l Marke t Ana lys i s Research and Consu l t ing ( IMARC) . No pa r t o f t h i s pub l i ca t ion may be
rep roduced , repackaged , red i s t r i bu ted o r res o ld i n who le o r i n any pa r t . The pub l i ca t ion may a l so
no t be used i n any f o rm o r by and means g raph i c e lec t ron ic o r mechan ic a l , i nc lud ing pho tocopy ing ,
reco rd ing , t ap ing o r by i n fo rmat i on s to rage o r re t r ieva l , o r by any o the r f o rm, w i t hou t the exp ress
c ons en t o f I n t e rna t iona l Marke t Ana lys i s Research and Consu l t i ng ( IMARC) .
Disc la imer : Al l con ten ts and da ta o f t h i s pub l i c a t i on , i nc lud ing fo recas t s , da ta ana lys i s and op in ion
have been based on in f o rmat ion and sources be l ieved to be accu ra te and re l iab le a t t he t ime o f
pub l i sh ing . In t e rna t i ona l Ma rke t Ana l ys is Research and Consu l t ing makes no rep resen ta t ion o f
war ran t y o f any k ind as to t he acc u racy o r comp le teness o f any I n fo rmat i on p rov ided . IMARC
accep ts no l i ab i l i t y wha tsoever f o r any los s o r damage resu l t i ng f rom op in ion , e r ro rs o r
i naccu rac ies i f any f ound th is pub l i ca t ion .
IMARC, IMARC Group and G loba l Therapy I ns igh t Ser i es a re reg is t e red t rademarks o f I n te rna t iona l
Marke t Ana lys i s Research and Consu l t ing . A l l o the r t rademarks used i n th i s pub l i ca t i on a re
reg i s te red t rademarks o f t he i r r espec t i ve compan ies .
Contact Us
Visit us at :
https://www.imarcgroup.com
TELEPHONE: +1-631-791-1145
E-MAIL: [email protected]
Comments